Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.

Alaunos Therapeutics, Inc.

EV Therapeutics develops off-the-shelf neoantigen-based immunotherapies from tumor-derived extracellular vesicles (EVs) and formulates proprietary therapeutic vaccines to enhance cancer treatment efficacy. self-described.

EV Therapeutics

Therini Bio develops immunotherapies for neuroinflammation in diseases driven by vascular dysfunction. It focuses on a clinical-stage pipeline aimed at treating severe neurological and retinal diseases.

Therini Bio

Umoja Biopharma develops integrated platform therapeutics that reprogram the immune system to target cancer cells and generate lasting remissions.

Umoja Biopharma

Alaunos is a clinical stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. The company targets Neoantigens arising from genomic mutations.

Metric
Company Name	Alaunos Therapeutics, Inc.	EV Therapeutics	Therini Bio	Umoja Biopharma
Symbol	TCRT
MSH ID	COM:ALAUNOS	COM:EVTHERAPEUTICS	COM:THERINIBIO	COM:UMOJA-BIOPHARMA
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Biotechnology	Biotechnology
Country	US	US	US	US
Stage
Employee Count	1	1
Website	alaunos.com	evtherapeutics.com	therinibio.com	umoja-biopharma.com
LinkedIn			therinibio
Founders

Metric
Market Cap	9.61M
Enterprise Value
Monthly Web Traffic		6.83K
Web Traffic Growth		-0.19
Valuation
Raised Capital

Metric
Revenue	5K
Revenue (LTM)
Revenue (NTM)
Gross Profit	-4.80M
EBITDA	-34.27M
Operating Income	-34.27M
Net Income	-35.14M
EPS	-0.00
Diluted EPS	-0.00
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	-217
Operating Profit Margin	-2.32K
EBITDA Margin	-6.85K
Net Profit Margin	-2.43K
Return on Equity	-1.41
Return on Assets	-1.87
Return on Capital Employed	-2.36

COM:ALAUNOS

Alaunos Therapeutics

Last Close

2.32

22/11 21:00

Market Cap

9.61M

Beta: -

Volume Today

7.88K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-14.38
P/B Ratio	37.65
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	4.36K
EV Multiple	-0.43

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding	0.00
Operating Cycle	243.33
Cash Conversion Cycle	141.48
Asset Turnover	0.00

Metric
Operating Cash Flow	-30.14M
Free Cash Flow	-30.34M
Cash Flow to Debt
Operating Cash Flow/Sales	-1.99K
Free Cash Flow Yield	-0.86

Metric
Cash & Equivalents	6.06M
Accounts Receivable	3K
Inventory
Goodwill
Debt to Capitalization	0.08
Debt to Assets	0.06
Current Ratio	2.75
Quick Ratio	5.16

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	228.47
R&D to Revenue	1.40K
SG&A to Revenue	1.30K